A principal focus of Takeda’s Corporate Social Responsibility activities is to “put the patient at the center.” How does patient-centricity help a company and lead to a secure future?
There are still a lot of diseases with significant unmet medical needs, which can be very debilitating and restricting for patients. Additionally, sometimes there are gaps in understanding patient needs. For example, physicians tend to be more satisfied than patients with the treatment provided, and therefore it is important to understand the real customer satisfaction. It is very important for us to understand patients’ needs and the impact of diseases on their lives. Takeda’s approach is to focus on the patient and earn their trust, which builds the company’s reputation. The business viability will naturally follow.
Can you share an example of an innovation that began with focusing on the patient or the customer?
One example is NINLARO, which launched in the U.S. in December 2015 as a treatment option for multiple myeloma and was developed with patients’ lifestyle in mind. With NINLARO, we have achieved a remarkable innovation: the first and only, once-weekly oral proteasome inhibitor indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy. NINLARO enables patients to get the benefit of a proteasome inhibitor through an all-oral treatment regimen for the first time...
Read the rest of this interview on the Index Website or on iBIOBQ
|
